Clopidogrel
Product Images NDC 50436-9986

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 50436-9986). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

This description describes the effect of the co-administration of proton pump inhibitors (PPIs) on the exposure to Clopidogrel active metabolite following multiple doses of Clopidogrel Bisulfate 75 mg. The figure shows the mean and 90% confidence interval of the effect of four different PPIs, Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, on the active metabolite AUC. It also shows the change, relative to Clopidogrel Bisulfate administered alone, in the exposure to the active metabolite following the co-administration of different PPIs.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

This is a description of a chart or graph showing the cumulative event rate (in percentages) for cardiovascular death, myocardial infarction, and stroke over a 12-month follow-up period. The data includes results for both placebo and clopidogrel bisulfate (both taken with aspirin) and indicates that the clopidogrel group had a lower event rate. The graph also notes that other standard therapies were used as appropriate and provides a P value for statistical significance.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

This appears to be a table with various categories and data sets. It is not clear what the data represents as the headings are not fully readable and the text contains several errors due to .*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

This is a clinical trial study comparing the effects of placebo and clopidogrel in reducing the death rate before first discharge. The study found that the percentage of deaths was higher in the placebo group (8.1%) compared to the clopidogrel group (7.5%), showing a 7% risk reduction with clopidogrel. The study also measured the effect over 28 days, with a statistically significant reduction in mortality noted after day 7.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

This is a report on a clinical trial comparing the efficacy of Placebo and Clopidogrel in reducing the risk of cardiovascular events. The number of patients who experienced events while on Placebo was 2310 (10.1%) while on Clopidogrel it was 2121 (9.2%). A proportional risk reduction of 9% in death, re-infarction, or stroke was observed in the Clopidogrel group compared to the Placebo group, with a p-value of 0.002. The timeline of the trial was up to 28 days, and the data was collected at various intervals during this period.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

This appears to be a graph showing the cumulative event rate (in percentages) for fatal or non-fatal vascular events in relation to the use of Aspirin and Clopidogrel Bisultate over a period of 36 months of follow-up.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

This text appears to be a table with four qualifying conditions: stroke, MI, PAD, and overall. The table includes information about the number of individuals with each condition and the percentage of those individuals taking either Clopidogrel Bisulfate or Aspirin. The table also includes a section labeled "Favors" with corresponding years and "Hazard Ratio (95% C1)" at the end. Without additional context, it's unclear what the numbers in these sections represent.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

FDA Label Image

Label Image (Lbl504369986)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.